Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors
Journal of Computer-Aided Molecular Design · 2025
DOI: 10.1007/s10822-025-00654-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Computer-Aided Molecular Design, 2025. Verfasst von Anatoliy A Bulygin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch (SB) of RAS, Novosibirsk, Russia. abulygin@niboch.nsc.ru. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, Protease Inhibitors, COVID-19 Drug Treatment. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Russian state.
Abstract (Originalsprache)
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the third case of widespread coronavirus infection. Together with the other two viruses, the SARS-CoV-2 virus is highly pathogenic, and some strains have a mortality rate of more than 1%. Moreover, it has become clear that coronaviruses mutate quite often, which reduces the effectiveness of available vaccines and forces the regular creation of new ones. The main viral protease Mpro is a suitable target for direct-acting drugs. Currently, there is only one recommended anticoronavirus drug, nirmatrelvir, which, however, does not have all the properties necessary for widespread and effective use. Thus, the development of a highly selective and effective protease inhibitor that can be taken orally still remains relevant. In this work, we performed an in-depth literature review of Mpro inhibitor studies and conducted extensive molecular dynamics simulations of Mpro-inhibitor complexes with computational prediction of binding ability and ADME (absorption, distribution, metabolism and excretion) properties of new compounds. On the basis of the literature review we composed a set of criteria that a potent inhibitor must meet. Then we created a set of possible inhibitors and their parts, which presumably allows all the necessary properties, namely, high affinity for the viral enzyme, selectivity, bioavailability and solubility, to be achieved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch (SB) of RAS, Novosibirsk, Russia. abulygin@niboch.nsc.ru.
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch (SB) of RAS, Novosibirsk, Russia. Nikita.Kuznetsov@1bio.ru.
- Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia. Nikita.Kuznetsov@1bio.ru.
Förderung
- Russian state
Zitieren
APA
Bulygin, A. A., & Kuznetsov, N. A. (2025). Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors. Journal of Computer-Aided Molecular Design. https://doi.org/10.1007/s10822-025-00654-9
Vancouver
Bulygin AA, Kuznetsov NA. Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors. Journal of Computer-Aided Molecular Design. 2025. doi:10.1007/s10822-025-00654-9
BibTeX
@article{Bulygin2025,
author = {Bulygin, Anatoliy A and Kuznetsov, Nikita A},
title = {Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors},
journal = {Journal of Computer-Aided Molecular Design},
year = {2025},
doi = {10.1007/s10822-025-00654-9}
}
EUVIMED